QYResearch Reviewed: In 2016, global revenue of bacterial vaginosis drug is nearly 772 M USD

Bacterial Vaginosis Drug is used for the treatment of Bacterial Vaginosis (BV), which also known as vaginal bacteriosis or Gardnerella vaginitis, a disease of the vagina caused by excessive bacteria.

According to QYResearch, In the last several years, global market of bacterial vaginosis drug developed smoothly, with an average growth rate of 3.01%. In 2016, global revenue of bacterial vaginosis drug is nearly 772 M USD.

The classification of bacterial vaginosis drug includes Rx and OTC, and the proportion of OTC in 2016 is about 72%.

Bacterial vaginosis drug is widely sold in hospital, pharmacy and other field. The most proportion of bacterial vaginosis drug is sold in pharmacy, and the revenue in 2016 is about 423 M USD.

USA region is the largest supplier of bacterial vaginosis drug, with a revenue market share nearly 32% in 2016. Europe is the second largest supplier of Bacterial Vaginosis Drug, enjoying revenue market share nearly 30% in 2016.

USA and Europe are the largest consumption places, with the consumption market share nearly 28% in 2016.

Market competition is intense. Bayer, Pfizer, Sanofi, Piramal, Abbott, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.

More Info: http://www.qyresearchglobal.com/goods-435290.html

This article was first released by QYResearch, if reproduced, please indicate the source.
Marketing: sales@qyresearch.com
Media Contact: press@qyresearch.com